Stock ALDVI ADVICENNE
Add to a list
To use this feature you must be a member
Log inSign up

Financials Advicenne

Equities

ALDVI

FR0013296746

Pharmaceuticals

Market Closed - Euronext Paris
Other stock markets
 11:25:00 2024-04-26 am EDT 		5-day change 1st Jan Change
1.68 EUR -1.75% Intraday chart for Advicenne -0.59% -36.84%
Apr. 08 Advicenne S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 25 Advicenne: ODD designation in cystinuria CF

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 71.17 84.19 94.11 45.4 32.68 20.63 -
Enterprise Value (EV) 1 54.99 81.21 93.96 55.83 32.68 43.33 17.43
P/E ratio -5.06 x -5.68 x -7.1 x -3.94 x -3.97 x -2.63 x 0.82 x
Yield - - - - - - -
Capitalization / Revenue 27.5 x 23.6 x 28.5 x 19.4 x 11.1 x 4.91 x 3.59 x
EV / Revenue 21.3 x 22.8 x 28.5 x 23.8 x 11.1 x 10.3 x 3.03 x
EV / EBITDA -4.01 x -5.83 x -7.82 x -5.74 x -5.23 x -7.34 x 0.65 x
EV / FCF -5.28 x - - -6.03 x - -4.33 x 0.83 x
FCF Yield -18.9% - - -16.6% - -23.1% 120%
Price to Book - - - - - - -
Nbr of stocks (in thousands) 8,088 8,419 9,885 9,934 12,287 12,283 -
Reference price 2 8.800 10.00 9.520 4.570 2.660 1.680 1.680
Announcement Date 3/13/20 4/28/21 3/31/22 3/30/23 3/28/24 - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 2.584 3.564 3.3 2.341 2.942 4.2 5.75
EBITDA 1 -13.71 -13.92 -12.02 -9.725 -6.246 -5.9 26.75
EBIT 1 -14.25 -14.14 -12.44 -10.06 -6.457 -6.3 10.3
Operating Margin -551.39% -396.63% -377.09% -429.69% -219.48% -150% 179.13%
Earnings before Tax (EBT) - - - - - - -
Net income 1 -13.71 -14.85 -12.43 -11.47 -7.031 -7.9 22.3
Net margin -530.75% -416.55% -376.58% -489.96% -238.99% -188.1% 387.83%
EPS 2 -1.740 -1.760 -1.340 -1.160 -0.6700 -0.6400 2.060
Free Cash Flow 1 -10.41 - - -9.262 - -10 20.95
FCF margin -402.86% - - -395.64% - -238.1% 364.35%
FCF Conversion (EBITDA) - - - - - - 78.32%
FCF Conversion (Net income) - - - - - - 93.95%
Dividend per Share - - - - - - -
Announcement Date 3/13/20 4/28/21 3/31/22 3/30/23 3/28/24 - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - 10.4 - 22.7 -
Net Cash position 1 16.2 2.97 0.15 - - - 3.2
Leverage (Debt/EBITDA) - - - -1.072 x - -3.847 x -
Free Cash Flow 1 -10.4 - - -9.26 - -10 21
ROE (net income / shareholders' equity) -58.9% - -694% - - - 372%
ROA (Net income/ Total Assets) - - - - - 61.3% 177%
Assets 1 - - - - - -12.89 12.6
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 1 0.93 - - 0.12 - 1 0.75
Capex / Sales 35.99% - - 4.91% - 23.81% 13.04%
Announcement Date 3/13/20 4/28/21 3/31/22 3/30/23 3/28/24 - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Advicenne

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.68 EUR
Average target price
6.9 EUR
Spread / Average Target
+310.71%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
ADVICENNE Stock Advicenne
-36.84% 22.03M
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.09% 15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. ALDVI Stock
  4. Financials Advicenne